Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Short Interest Update

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) was the recipient of a large drop in short interest during the month of May. As of May 29th, there was short interest totaling 40 shares, a drop of 67.5% from the May 14th total of 123 shares. Based on an average daily trading volume, of 53 shares, the short-interest ratio is currently 0.8 days. Approximately 0.0% of the shares of the company are sold short.

Orion OYJ Stock Performance

OTCMKTS:ORINY opened at $37.99 on Thursday. The firm’s fifty day moving average price is $37.99 and its 200 day moving average price is $37.96. Orion OYJ has a 1-year low of $25.95 and a 1-year high of $42.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.77 and a quick ratio of 1.13. The firm has a market cap of $10.72 billion, a price-to-earnings ratio of 17.43 and a beta of 0.08.

Orion OYJ (OTCMKTS:ORINY) last posted its quarterly earnings data on Thursday, April 23rd. The company reported $0.37 earnings per share for the quarter. Orion OYJ had a net margin of 27.14% and a return on equity of 49.17%. The firm had revenue of $488.80 million for the quarter.

Orion OYJ Company Profile

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.